Pyxis Oncology Inc (PYXS) — Titan Protect Analysis

PYXS

Pyxis Oncology Inc

Healthcare · ·

$1.78

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$109M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.40

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-121.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$7.00

+293% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Pyxis Oncology Inc

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monothera

https://www.pyxisoncology.com

Country: United States Employees: 56 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.202

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0384

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.386

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-31.4%

Historical annualised return based on price data

Max Drawdown

-81.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.43

Moves slightly more than the broader market

52W High

$5.55

68% below the year high

52W Low

$0.97

84% above the year low

Avg Volume

492,668

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.30

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

58.39

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

82.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-600.2%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$14M

Total revenue over the last 12 months

Net Income

$-81,735,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$9.00

Target Median

$7.00

Target Low

$5.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go